Author: Henry Miller

Miller talks about which of the Moderna and Pfizer vaccines are better for younger and older Americans based on the available data. Batchelor and Miller also discuss the new COVID-19 coronavirus mutation found in the UK and what it means for vaccines and shutdown orders. Miller also explains the long history of other coronavirus vaccines mainly used in the livestock industry and why the new "human" vaccine is different through the use of the messenger RNA technique. ...

Since the beginning of the coronavirus pandemic, there have been many thousands of articles and commentaries published on almost every imaginable aspect of the SARS-Cov-2 virus and the COVID-19 pandemic it has caused. They have appeared online, in journals, on preprint servers, in newspapers, and on blogs. As much as we might try to keep up, there will always be important facts or developments we might have missed, so below are a few that should help us understand some of...

Henry Miller, M.S., M.D., joins the nationally-syndicated Lars Larson Show based in Portland, Oregon, to discuss little known facts about the rollout and use of the current COVID-19 coronavirus vaccines. One of the main points Dr. Miller makes is the difference in how the two vaccines have performed in various age groups. With the Moderna vaccine, data shows that it is more effective with older Americans. According to the New England Journal of Medicine, the Pfizer vaccine had better efficacy with...

Dr. Henry Miller, M.S., M.D., joints the nationally-syndicated Lars Larson Show based out of Portland, Oregon, to discuss the latest issues with the production and distribution of the COVID-19 vaccine. Dr. Miller's interview begins at the 47:00 minute mark. Miller talks about his disappointment with the vaccine distribution, but also says that it wasn't entirely unexpected. When you put distribution on the states and farther down the chain, your going to have issues. Miller also says that the timing of the...

To the editor of the Wall Street Journal: Your editorial contains the statement: "There's no evidence that a three-week review is needed." You know this how, exactly? Has anyone at the Journal seen the data (which run to hundreds of thousands of pages)? Has anyone at the Journal ever seen, let alone touched, an application for approval of a drug or vaccine? I have. As an FDA reviewer, I found extraordinary complexity, and sometimes shortcomings or inconsistencies, in many submissions ....

Public Health And Economic Growth Are Two Sides Of The Same Coin Vaccination of high-risk groups against SARS-CoV-2, the virus that causes COVID-19, has begun in earnest – and not a moment too soon because the trends in the United States are moving in the wrong direction. On December 13, records were set for 7-day averages of daily cases ((211,494), the number of people hospitalized (106,656), and daily deaths (2,427); and with the Christmas and New Year’s holidays approaching, we can expect worsening...

It should be obvious by now that the adoption of measures to prevent the spread of coronavirus SARS-CoV-2, which causes COVID-19, has become politicized. Consider the presidential campaigns: President Donald Trump held large indoor rallies with mostly mask-less supporters, while President-elect Joe Biden seemed to have a mask sutured to his face and spent much of the campaign in isolation. Gallup surveys published in November show that partisanship remains the most significant driver of the public’s perceptions of the COVID-19 pandemic and...

We are in the midst of a pandemic of historic proportions. COVID-19 has killed more than a quarter of a million Americans, caused pain and suffering to many more, damaged a thriving economy, and caused great public anxiety. And it promises to get worse before it gets better. The numbers of cases, the percentage of positive test results, and hospitalizations are all trending upwards. That bodes particularly ill as the Thanksgiving and Christmas holidays approach, tempting many of us into high-risk situations. Relief...

By Henry Miller, M.S., M.D. and John J. Cohrssen Presumptive President-Elect Joe Biden’s transition organization has published an initial plan to “beat” the rapidly worsening Covid-19 pandemic. Though it is essential and not wholly unreasonable, some parts seem to have been highjacked by a political agenda that contains tangentially related issues. The plan’s sole focus should be on the difficult and complex problem of interrupting the runaway pandemic while maintaining a viable economy. It needs a sensible organizational structure to use the available...

The John Batchelor Show talks to PRI's Dr. Henry Miller about the effectiveness of a COVID-19 Pfizer vaccine compared to industry standards. Miller explains the baselines based on current vaccines and talks how a 90 percent effective vaccine could create herd immunity. Batchelor and Miller also talk about the logistics of storing, creating, and producing the vaccine including extreme cold storing requirements and a short shelf life. ...

Dr. Henry Miller breaks down the latest announcement from Pfizer about a potential COVID-19 vaccine and look at the numbers around placebo and side-effects. Larson and Miller also talk about the impact of mild symptoms and what those could mean for at-risk Americans and those with co-morbidities and if the vaccine has "sterilizing immunity." Moderna has also announced a potential vaccine. Lars Larson National Podcast · Lars Larson National Podcast 11-10-20...

By Andrew Fillat and Henry Miller, M.S., M.D. The announcement last week by Pfizer that its COVID-19 vaccine has been shown in large-scale clinical trials to be more than 90% effective at preventing symptomatic infection has been much in the news. [After this article was posted, biotechnology firm Moderna, Inc., announced that its vaccine was 94.5% effective.] It is especially welcome news, given the skyrocketing numbers of COVID-19 cases, percentage of positive tests, and hospitalizations in much of the nation. However, to state the obvious,...

Henry Miller, M.S., M.D., joins the John Batchelor Show to discuss an alleged mutation of COVID-19 in Europe. Miller explains the difference between flu or cold mutations and how these mutations to mink farms could jeopardize current novel coronavirus vaccines. Several of the mutations in Denmark and the Netherlands have moved directly from animal to human, according to the Wall Street Journal. ...

Dr. Henry Miller, M.S., M.D. talks about the impact of a pending vaccine in the United States. Miller also talks about continuing treatments like remdisivir, zinc, and other common treatments to help fight the COVID-19 and how they will play an important role as more vaccine are developed. Larson and Miller also talk about how COVID-19 has been found to impact the immune system and what hospitals and health care officials can do to lessen the impact of the coronavirus. Lars...

President Trump’s COVID-19 recovery has thrust into the spotlight the possibilities of novel, experimental therapies for this potentially deadly disease.  During his stay at Walter Reed National Military Medical Center, he was treated with at least three drugs that have since received substantial attention in the media: the anti-viral remdesivir, the glucocorticoid steroid dexamethasone, and the monoclonal antibody cocktail REGN-COV2. While evidence suggests these drugs may be effective (and remdesivir just received full marketing approval from the FDA), there are other potential game-changers...

For the more than 7 million Americans who inject insulin, Friday will mark an important anniversary: 38 years since the Food and Drug Administration (FDA) approved the use of human insulin synthesized in genetically engineered bacteria. This momentous event launched a revolutionary new era in pharmaceutical development, and, as the FDA medical reviewer of the product and the head of the evaluation team at the time, I had a front-row seat. To commemorate the event, I open a bottle of champagne every...

PRI's Dr. Henry Miller joins the John Batchelor Show to discuss the lateset updates on a coronavirus vaccine. Dr. Miller talks about President Donald Trump's treatment with remdisivir during his positive coronavirus diagnosis. Batchelor and Miller talk about the push by the American government decades ago to use advertising to influence the public to take the polio vaccine and what the government can do now to encourage everyone to take a COVID-19 one. Miller also breakdowns how effective a vaccine...

By Henry Miller, M.S., M.D. and Andrew Fillat Americans -- so desperate to end the need for masks, social distancing, and limited access to restaurants, salons, concerts, and schools -- will surely be clamoring for a vaccine as soon as it’s available. Or will they?  Recent polls suggest that only about 40% of Americans would take the vaccine. It is vital that this number be increased. But how? Let's explore this issue. There is widespread anticipation of vaccines to prevent COVID-19 infections so that...

The COVID-19 pandemic has intensified various political and economic flashpoints. From health care to housing, drug pricing to food pricing, the societal strain of the pandemic has renewed the urgency and raised the stakes for long-standing issues. The increasingly heated debate about the rules and regulations governing medical device servicing is an exemplar of this new reality. Although the dispute between independent aftermarket repair businesses and original equipment manufacturers (OEMs) isn’t new, it has shifted from auto repair, farm equipment, and...

“Don’t Fight the Fed” is an old saying that advises business investors to align their choices with the actions of the Federal Reserve System, the U.S. central banking system which has several potent tools at its disposal to influence stock prices. When it comes to understanding and preventing the spread of infectious diseases, an analogous maxim might be, “don’t fight science,” or, more specifically, epidemiology. A pertinent example is the outbreak of COVID-19 among President Trump, First Lady Melania Trump, senior presidential advisor Hope...